Portrait-022-LOW 2_edited_edited_edited.png

Jean-Charles BROSSE

Senior Advisor

 

PhD PHARMACY

HEALTH ECONOMICS

Joined Positive Capital in 2016

  • icon-email
  • LinkedIn
  • Logo Medium

"Advising companies operating in the life sciences for more than 15 years has given me a sense of the markets, their orientations and an ability to identify opportunities.

 

I like to take up challenges to succeed, with a strong interest in technological and innovative subjects. I believe in the synergies of a team with humility, respect and commitment."

My profile

My passions are the development of successful strategies which achieve commercial success and profitability with a strong focus on life sciences.

I believe in companies managed by an ambitious team sticking on facts, markets, and robust vision of product development. Innovation is obviously the holy grail but only if it meets the actual market’s needs. But above all I need to feel a definite human capacity in teams.

My passions arose during my careers in life sciences in sales, marketing and management and international business development in consultancy. I worked in several spaces including the biological diagnostic, the pharmaceuticals, the pharmaceutical biotech, the CDMO services, the Medical technologies and Healthcare. From these alternate roles, I gained a deep market vision and the sense of business triggers. That is a solid basis for understanding any new project in life sciences and health, for detecting a promising innovation and business project.

This was a clear stepping-stone to the funding arena and private equity adding the corporate-wide. My business development experience facilitated the jump from the project to the corporate level. I appreciate a lot working alongside the client teams building a close partnership to get success.

I developed lots of relations with the investment community to understand their vision beyond their fields of interest and needs. Developing a clear space of mutual respect and common interest is obviously fruitful.

Extending the business development experiences to the M&A has been rational to find synergies and potential selling-out or acquisition.

At last, this duality of technical and financial purposes is the DNA of Positive Capital which is highly and interestingly developed in the Deeptech arena such as sustainability. We hope that Positive Capital will become a partner of choice in this matter, and we work intensively toward this objective.